Opthea to Participate in November Investor Conferences
Virtual Bell Potter Healthcare Conference, November 18, 2024
Jefferies London Healthcare Conference, November 19, 2024
MELBOURNE, Australia and PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.
Conference details are as follows:
| Bell Potter Healthcare Conference | |
| Presentation: | Monday, November 18, 2024, 3:00 PM AEDT (Virtual) |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
| The webcast will be accessible under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com. | |
| Jefferies London Healthcare Conference 2024 | |
| One-on-One Meetings: | Tuesday, November 19, 2024 |
| Participant: | Frederic Guerard, PharmD, CEO, Opthea |
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: [email protected]
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: [email protected]
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: [email protected] Web: www.opthea.com
Source: Opthea Limited
